Futura Medical shares rise on ED licensing deal with Haleon
Futura Medical
33.50p
16:34 26/07/24
-0.30%
-0.10p
Shares in Futura Medical gained on Monday after the company said it signed a licensing deal with consumer heath care giant Haleon for the rights to exclusively commercialise its topical, gel-based erectile dysfunction treatment MED3000 in the USA.
FTSE 100
8,285.71
16:45 26/07/24
n/a
n/a
FTSE 350
4,586.28
16:45 26/07/24
n/a
n/a
FTSE AIM All-Share
778.91
16:25 26/07/24
n/a
n/a
FTSE All-Share
4,544.36
16:29 26/07/24
n/a
n/a
Haleon
353.00p
16:34 26/07/24
1.35%
4.70p
Pharmaceuticals & Biotechnology
22,767.31
16:45 26/07/24
1.27%
284.71
Futura will receive an initial upfront payment of $4m, royalty payments on all sales of MED3000 by Haleon and potential commercial and performance-driven sales milestone payments totalling between $5m and $45m payable over the course of several years